These studies delve into the relationship between macrophages and immunotherapy in non-small cell lung cancer (NSCLC), including investigating how autologous tumor vaccines enhance T-cell immunity against tumor-associated antigens like HER-2/neu protein when combined with granulocyte-macrophage colony-stimulating factor as an adjuvant (27). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.